Sitagliptin With Simvastatin
Recommended EndocrinologyAuthority Required
Type 2 diabetes mellitus and hypercholesterolaemia in patients currently receiving treatment with simvastatin and who satisfy the criteria for prescribing DPP-4 inhibitors.
2
Submissions
2012–12
On the record
—
ICER range
Cost-min
Cost basis
Decision on record
- Meeting Nov 2012 Recommended Type 2 diabetes and high cholesterol levels
Access path
- Nov 2012Recommended · restricted
Evidence: RCT → Single-arm
- Nov 2012Recommended · restricted
Evidence: RCT → Single-arm
- PBS listing · Authority Required
RecommendedDeferredNot recommended
Cost-effectiveness
Cost-minimisation analysis; no ICER calculated
The PBAC considered that the requirements under the National Health Act for recommending listing of a product were met, provided that, as claimed in the submission the listing is cost neutral to the PBS. PBAC · 2012
Cost-effectiveness accepted
Decision context
PopulationPatients with type 2 diabetes currently receiving treatment with simvastatin who satisfy the criteria for prescribing DPP-4 inhibitors, with HbA1c greater than 7% or blood glucose levels greater than 10 mmol/L in more than 20% of tests despite treatment with metformin or a sulfonylurea.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Nov 2012 | Recommended · restricted | sitagliptin and simvastatin taken concomitantly | — | RCT |
| Nov 2012 | Recommended · restricted | sitagliptin and simvastatin taken concomitantly | — | Single-arm |
Similar precedents
Regulatory · TGA
Label narrower than PBS population — PBAC restricts to later-line use in patients already on simvastatin and meeting DPP-4 inhibitor prescribing criteria; TGA label is broader.